Europe could overthrow the U.S. as a leader in the biotech-drug industry if U.S. lawmakers decide to shorten market exclusivity for brand-name biopharmaceuticals under health reform legislation, writes Benedetto Della Vedova, former member of the European Parliament. A proposal to provide five to seven years of protection would stifle innovation and diminish the chance of U.S. companies to be globally competitive, giving way for European firms to create the next generation of biologic drugs, Della Vedova writes.

Related Summaries